{
    "nct_id": "NCT03906071",
    "official_title": "A Randomized Phase 3 Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE",
    "inclusion_criteria": "* Diagnosis of Non-Squamous Non-Small Cell Lung Cancer\n* Receipt of at least one but not more than two prior treatment regimens in the advanced setting\n* Prior treatment with PD-1/PD-L1 checkpoint inhibitor therapy and platinum-based chemotherapy in combination or in sequence (i.e., platinum-based chemotheraphy followed by checkpoint inhibitor therapy)\n* Most recent treatment regimen must have included a checkpoint inhibitor therapy with radiographic disease progression on or after treatment\n* Candidate to receive docetaxel as second or third line therapy\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Uncontrolled brain metastases\n* Tumors that have tested positive for EGFR, ROS1, ALK mutations, or ALK fusions\n* Unacceptable toxicity with prior checkpoint inhibitor therapy\n* Receipt of systemic anti-cancer therapy post checkpoint inhibitor therapy, other than maintenance chemotherapy\n* Impaired heart function",
    "miscellaneous_criteria": ""
}